Article info
PDFLetter
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor α biological treatments according to the current guidelines
- Correspondence to:
Dr H Direskeneli
Division of Rheumatology, Marmara Medical School Hospital, Tophanelioglu Cad. 13/15, 81190, Altunizade, Istanbul, Turkey; direskenelisuperonline.com
Citation
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor α biological treatments according to the current guidelines
Publication history
- Accepted January 30, 2005
- First published August 12, 2005.
Online issue publication
April 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by Annals of the Rheumatic Diseases